Dynamic nerve stimulation in combination with other eating disorder treatment modalities

• US 8,295,926 B2
• Filed: 10/23/2009
• Issued: 10/23/2012
• Est. Priority Date: 06/02/2006
• Status: Active Grant

• Current Assignee: Advanced Neuromodulation Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Advanced Neuromodulation Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Dobak, John D. III
• Primary Examiner(s): Manuel, George
• Application Number:
  US12/604,953
• Publication Number:
  US 20100106207A1
• Time in Patent Office: 1,096 Days
• Field of Search: 607/3
• US Class Current: 607/3
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 38/2264 Obesity-gene products, e.g. leptin
• CPC Class Codes: A61K 41/00 Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 1/36007 of urogenital or gastrointestinal organs, e.g. for incontinence control
• CPC Class Codes: A61N 1/36017 with leads or electrodes penetrating the skin
• CPC Class Codes: A61N 1/36085 Eating disorders or obesity

Abstract

A method for treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and/or administering a weight loss drug.

Claims

1. A method of maintaining lean muscle mass during weight loss comprising:

administering a weight loss therapy; and

electrically stimulating a splanchnic nerve of a mammal using a ramp-cycling stimulation therapy, wherein the mammal losses weight and substantially maintains lean muscle mass.

2. The method according to claim 1, wherein at least 5% of weight loss is attributable to loss in central fat.

3. The method according to claim 1, wherein the weight loss therapy is a pharmaceutical.

4. The method according to claim 3, wherein less than 50% a normally prescribed dosage of the pharmaceutical is administered.

5. The method according to claim 1, wherein a pharmaceutical is administered in parallel with the electrical stimulation.

6. The method according to claim 1, wherein a pharmaceutical is administered in series with the electrical stimulation.

7. A method of preventing or treating an eating disorder in a mammal comprising:

electrically stimulating a splanchnic nerve of the mammal using a ramp-cycling stimulation therapy; and

administering a weight loss composition in a pharmaceutically effective amount to produce weight loss in the mammal.

8. The method of claim 7, wherein the weight loss composition comprises an appetite suppressant.

9. The method of claim 8, wherein the appetite suppressant is one or more selected from the group consisting of a noradrenergic agent, a serotonergic agent, and an adrenergic/serotonergic agent.

10. The method of claim 9, wherein the appetite suppressant is one or more selected from the group consisting of phenylpropanolamine, phentermine, fenfluramine, dexfenfluramine, fluoxetine, sibutramine.

11. The method of claim 7, wherein the weight loss composition comprises a thermogenic agent.

12. The method of claim 11, wherein the thermogenic agent is one or more selected from the group consisting of a sympathomimetic and a selective Beta 3-adrenergic agonist.

13. The method of claim 7, wherein the weight loss composition comprises a digestive inhibitor.

14. The method of claim 7, wherein the digestive inhibitor is a lipase inhibitor.

15. The method of claim 14, wherein the lipase inhibitor is tetrahydrolipostatin.

16. The method of claim 7, wherein the weight loss composition comprises a cannabinoid antagonist.

17. The method of claim 7, wherein the weight loss composition comprises an anatagonist of a hormone or hormone receptor that increases food intake.

18. The method of claim 17, wherein the hormone is one or more selected from the group consisting of Neuropeptide Y, Orexins, and Ghrelin.

19. The method of claim 7, wherein the weight loss composition comprises an agonist of a hormone or hormone receptor that decreases food intake.

20. The method of claim 19, wherein the hormone is one or more selected from the group consisting of Glucagon-like-peptide 1, Cholecystokinin, Peptide YY (3-36), amylin, and melanocortins.

21. The method of claim 7, wherein the weight loss composition comprises one or more selected from leptin, a leptin stimulator, adiponectin, and an adiponectin stimulator.

22. The method of claim 7, wherein the weight loss composition comprises one or more selected from the group consisting of at least one appetite suppressant, at least one digestive inhibitor, at least one cannabinoid antagonist, at least one anatagonist of a hormone or hormone receptor that increases body weight, and at least one agonist of a hormone or hormone receptor that decreases body weight.

23. The method of claim 7, further comprising performing a surgical procedure configured to produce weight loss in the mammal.

24. A method of treating or prevent an eating disorder comprising:

electrically stimulating a splanchnic nerve of a mammal using a ramp-cycling stimulation therapy; and

performing a surgical procedure configured to produce weight loss in the mammal.

25. The method of claim 24, wherein the surgical procedure comprises a bypass.

26. The method of claim 25, wherein the surgical procedure comprises one or more selected the group consisting of jejuno-illeo bypass and a roux-en-Y gastric bypass.

27. The method of claim 24, wherein the surgical procedure comprises a gastric restrictive procedure.

28. The method of claim 24, wherein the gastric restrictive procedure comprises one or more selected from the group consisting of gastric banding, adjustable gastric banding, gastric stapling, and vertical banded gastroplasty.

29. The method of claim 24, wherein the surgical procedure comprises a partial biliopancreatic diversion.

30. The method of claim 24, wherein the surgical procedure comprises implanting a gastric displacement device.

31. The method of claim 24, wherein the gastric displacement device is a gastric balloon.

32. A method of preventing or treating an eating disorder comprising:

electrically stimulating a splanchnic nerve in a mammal to reduce a level of serum C-Reactive Protein (CRP) in the mammal using a ramp-cycling stimulation therapy; and

repeating splanchnic nerve stimulation in a manner to maintain a reduced level of CRP.

33. A method of preventing or treating an eating disorder comprising:

electrically stimulating a splanchnic nerve in a mammal to reduce a level of serum C-Reactive Protein (CRP) in the mammal; and

administering a weight loss drug in a dose configured to produce weight loss in the mammal.

34. The method of claim 33, wherein the step of administering a weight loss drug comprises administering exogenous leptin to the mammal.

35. The method of claim 33, wherein the administering of the weight loss drug is configured to maintain a reduced level of serum C-Reactive Protein (CRP).